Program in HIV Medicine

The Program in HIV Medicine focuses primarily on HIV pathogenesis and will build on and formalize the current network of investigators from the Medical School, the College of Veterinary Medicine, College of Pharmacy, and the School of Public Health.

Program Goals:

  • Support and sustain the existing strengths of the University of Minnesota in HIV research, which has focused predominately on HIV pathogenesis with more recent research investigating cures for HIV
  • Support the current network of HIV researchers in the Medical School, the College of Veterinary Medicine, College of Pharmacy, and the School of Public Health

Recent Publications

  • Herschhorn A. Indirect mechanisms of HIV-1 evasion from broadly neutralizing antibodies In vivo. ACS Infect Dis. 2023;9(1):5-8. doi: 10.1021/acsinfecdis.2c00573
  • Berard AR, Hensley-McBain T, Noël-Romas L, Birse K, Abou M, Westmacott G, McCorrister S, Smedley J, Klatt NR, Burgener AD. Mass spectrometry analysis of gut tissue in acute SIV-infection in rhesus macaques identifies early proteome alterations preceding the interferon inflammatory response. Sci Rep. 2023;13(1):690. doi: 10.1038/s41598-022-27112-y
  • Song H, Ling W, Zhao N, Plantinga AM, Broedlow CA, Klatt NR, Hensley-McBain T, Wu MC. Accommodating multiple potential normalizations in microbiome associations studies. BMC Bioinformatics. 2023;24(1):22. doi: 10.1186/s12859-023-05147-w
  • Rodriguez VJ, Salazar AS, Cherenack EM, Klatt NR, Jones DL, Alcaide ML. Assessing Intravaginal Practices in HIV Prevention Research: Development and validation of an intravaginal practices questionnaire. Arch Sex Behav. 2023;52(2):803-808. doi: 10.1007/s10508-022-02484-4
  • Pampusch MS, Sevcik EN, Quinn ZE, Davey BC, Berg JM, Gorrell-Brown I, Abdelaal HM, Rakasz EG, Rendahl A, Skinner PJ. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Front Immunol. 2023;14:1101446. doi: 10.3389/fimmu.2023.1101446
  • Wietgrefe SW, Duan L, Anderson J, Marqués G, Sanders M, Cummins NW, Badley AD, Dobrowolski C, Karn J, Pagliuzza A, Chomont N, Sannier G, Dubé M, Kaufmann DE, Zuck P, Wu G, Howell BJ, Reilly C, Herschhorn A, Schacker TW, Haase AT. Detecting sources of immune activation and viral rebound in HIV infection. J Virol. 2022;96(15):e0088522 doi: 10.1128/jvi.00885-22
  • Kroon, E,  Chottanapund, S, Buranapraditkun, S, Sacdalan, C, Colby, DJ, Chomchey, N, Prueksakaew, P, Pinyakorn, S, Trichavaroj, R, Vasan, S, Manasnayakorn, S, Reilly, C, Helgeson, E, Anderson, J, David, C, Zulk, J, de Souza, M, Tovanabutra, S, Schuetz, A, Robb, ML, Douek, DC, Phanuphak, N, Haase, A, Ananworanich, J, Schacker, TW. Paradoxically greater persistence of HIV RNA-positive cells in lymphoid tissue when ART is initiated in the earliest stage of infection, J Infect Dis. 2022; 225(12):2167–2175. doi: 10.1093/infdis/jiac089
  • Bellini N, Lodge R, Pham TNQ, Jain J, Murooka TT, Herschhorn A, Bernard NF, Routy JP, Tremblay CL, Cohen ÉA. MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4+ T cells. iScience. 2022;25(10):105234. doi: 10.1016/j.isci.2022.105234
  • Kirschman J, Marin M, Chen YC, Chen J, Herschhorn A, Smith AB 3rd, Melikyan GB. SERINC5 restricts HIV-1 infectivity by promoting conformational changes and accelerating functional inactivation of env. Viruses 2022;14(7):1388. doi: 10.3390/v14071388
  • Fletcher CV, Kroon E, Schacker T, Pinyakorn S, Chomont N, Chottanapund S, Prueksakaew P, Benjapornpong K, Buranapraditkun S, Phanuphak N, Ananworanich J, Vasan S, Hsu D; RV254/SEARCH 010 study Group. Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression. AIDS. 2022;36(7):985-990. doi: 10.1097/QAD.0000000000003201
  • Miller JS, Davis ZB, Helgeson E, Reilly C, Thorkelson A, Anderson J, Lima NS, Jorstad S, Hart GT, Lee JH, Safrit JT, Wong H, Cooley S, Gharu L, Chung H, Soon-Shiong P, Dobrowolski C, Fletcher CV, Karn J, Douek DC, Schacker TW. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: A phase 1 trial. Nat Med. 2022;28(2):392-400. doi: 10.1038/s41591-021-01651-9
  • Gustin AT, Thurman AR, Chandra N, Schifanella L, Alcaide M, Fichorova R, Doncel GF, Gale M Jr, Klatt NR. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. Am J Obstet Gynecol. 2022;226(2):225.e1-225.e15 doi: 10.1016/j.ajog.2021.09.018
  • Vilmen G, Smith AC, Benet HC, Shukla RK, Larue RC, Herschhorn A, Sharma A. Conformation of HIV-1 envelope governs rhesus CD4 usage and simian-human immunodeficiency virus replication. mBio. 2022;13(1):e0275221. doi: 10.1128/mbio.02752-21
  • Cervera H, Ratnapriya S, Chov A, Herschhorn A. Changes in the V1 Loop of HIV-1 Envelope glycoproteins can allosterically modulate the trimer association domain and reduce PGT145 sensitivity. ACS Infect Dis. 2021;7(6):1558-1568. doi: 10.1021/acsinfecdis.0c00899
  • Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, Chipman JG, Beilman GJ, Hoskuldsson T, Fourati S, Schmidt TE, Arumugam S, Lima NS, Moon D, Callisto S, Schoephoerster J, Tomalka J, Mugyenyi P, Ssali F, Muloma P, Ssengendo P, Leda AR, Cheu RK, Flynn JK, Morou A, Brunet-Ratnasingham E, Rodriguez B, Lederman MM, Kaufmann DE, Klatt NR, Kityo C, Brenchley JM, Schacker TW, Sekaly RP, Douek DC. Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell. 2021;184(15):3899-3914 doi: 10.1016/j.cell.2021.05.023
  • Klatt NR, Broedlow C, Osborn JM, Gustin AT, Dross S, O'Connor MA, Coronado E, Barnette P, Hensley-McBain T, Zevin AS, Muir R, Roederer A, Wangari S, Iwayama N, Ahrens CY, Smedley J, Moats C, Lynch RM, Haddad EK, Haigwood NL, Fuller DH, Manuzak JA. Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques. NPJ Vaccines. 2021;6(1):34 doi: 10.1038/s41541-021-00298-4

HIV Medicine